Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents

CORCEPT THERAPEUTICS INC

Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.
Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.
CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.
Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.